Lilly’s Name For Headache Treatment Moves Forward
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThe U.S. Food and Drug Administration has conditionally accepted the intended brand name of a prospective headache treatment from Indianapolis-based Eli Lilly and Co. (NYSE: LLY). Emgality, which recently showed positive results in a massive, late-stage study, is under development to fight episodic cluster headaches.
Lilly Bio-Medicines President Christi Shaw says "often confused with migraine, cluster headache is a neurological disease that has been characterized as ‘beyond excruciating’ by those who live with it. We are proud to present full results of this data, which represents potential hope for a resilient community of people struggling to prevent episodic cluster headache."
The results are detailed here.